Get started
Author

Colin L. Hickle

Observed name: Colin Hickle
ORCID: 0000-0001-5524-2523
Observed ORCID: 0000-0001-5524-2523
OpenAlex ID: A5025700122
Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
2021 · Stepan Chuprakov, Ayodele O. Ogunkoya, et al. · Bioconjugate Chemistry · 86
A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys
2015 · Melissa A Kachura, Colin Hickle, et al. · The Journal of Immunology · 29
A Novel HER2-targeted Antibody–drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels
2020 · Robyn M. Barfield, Yun Cheol Kim, et al. · Molecular Cancer Therapeutics · 13
PDF
Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al. · Molecular Cancer Therapeutics · 4
PDF
Data from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table 1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S6 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S7 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S8 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S7 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S6 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Works count: 32
Citation count: 132
H-index: 4
I10-index: 3
Year
Topic
Type